Skip to main content
    K

    Kiniksa Pharmaceuticals Ltd (KNSA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $95.11
    +0.88 (+0.93%)

    Market Cap: $7.40B

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Kiniksa Pharmaceuticals Ltd (KNSA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Kiniksa Pharmaceuticals (KNSA) has a market cap of $7.40B and an enterprise value of $7.32B. Revenue grew 58.19% over the last 12 months from the 12 months before. Its share count is up 4.65% from a year earlier.

    Total Valuation

    Enterprise value is 1.10% below the market cap, as cash exceeds debt.

    Market Cap$7.40B
    Enterprise Value$7.32B
    Latest price (Nov 17, 2026)$95.11

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateOct 27, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.79% in the quarter ended Sep 30, 2026 and grew 4.41% a year over 2 years.

    Shares Outstanding78.19M
    Shares Change (YoY)+4.65%
    Shares Change (QoQ)+0.79%
    Share Count Growth (2Y CAGR)+4.41%

    Valuation Ratios

    Sales and book value multiples are 7.9x and 10.5x. Its year-end P/E ranged from 5.8x to 97.4x from 2022 to 2025.

    P/E Ratio73.2x
    Forward P/E72.5x
    P/S Ratio7.9x
    Forward P/S7.1x
    P/B Ratio10.5x
    P/TBV Ratio10.7x
    P/FCF Ratio37.7x
    P/OCF Ratio37.2x
    PEG Ratio2.0

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 49.6x EBITDA and 37.3x free cash flow.

    EV / Earnings66.8x
    EV / Sales7.7x
    EV / EBITDA49.6x
    EV / EBIT50.1x
    EV / FCF37.3x

    Price Statistics

    The stock is up 135.89% over 52 weeks and trades 14.78% above its 50-day average.

    Beta (1Y)0.60
    52-Week Change+135.89%
    1-Month Change+19.67%
    3-Month Change+17.71%
    6-Month Change+78.31%
    5-Year Change+787.78%
    Total Return (1Y)+135.89%
    Total Return (3Y CAGR)+82.23%
    Total Return (5Y CAGR)+49.79%
    Return vs SPY (1Y)+118.84%
    Max Drawdown (1Y)-21.12%
    Max Drawdown (3Y)-34.14%
    Sharpe Ratio (1Y)1.57
    Correlation with SPY (1Y)0.16
    50-Day Average$82.86
    200-Day Average$63.33
    52-Week Range$37.02 to $99.31
    RSI (14 Days)58.0
    Average Volume (20 Days)908.54K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.91x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.91x
    Quick Ratio3.35x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 15.43% over the last 12 months, against a 5-year average of -7.06%.

    Return on Equity (ROE)15.43%
    Return on Assets (ROA)11.14%
    Return on Capital Employed (ROCE)18.47%
    ROE (5Y Average)-7.06%
    ROA (5Y Average)-5.00%
    ROIC (5Y Average)10.40%
    Asset Turnover1.12x
    Inventory Turnover4.83x
    Receivables Turnover34.86x
    Cash Conversion Cycle79 days

    Taxes

    Income tax took 25.03% of pretax income over the last 12 months.

    Income Tax (TTM)$36.58M
    Effective Tax Rate25.03%

    Scores

    KNSA has an Altman Z-Score of 17.95, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score17.95
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $945.96M over the last 12 months.

    Revenue$945.96M
    Revenue Growth (YoY)+58.19%
    Gross Profit$513.39M
    Operating Income$130.47M
    Pretax Income$146.15M
    Net Income$109.57M
    EBITDA$148.17M
    EBIT$146.15M
    Reported EPS (TTM)$1.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.23% of the $983.24M in total assets.

    Cash and Equivalents$81.66M
    Total Debt$0
    Net Cash$81.66M
    Net Cash Per Share$1.04
    Working Capital$558.24M
    Shareholder Equity$710.19M
    Book Value Per Share$9.08
    Tangible Book Value$695.69M
    Tangible Book Per Share$8.90
    Total Assets$983.24M
    Total Liabilities$273.05M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.64M of capital spending, operating cash flow left $197.20M of free cash flow.

    Operating Cash Flow$198.84M
    Capital Expenditures$1.64M
    Free Cash Flow$197.20M
    FCF Per Share$4.08
    Depreciation and Amortization$4.56M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 13.79%, against a 5-year average of -82.13%.

    Gross Margin54.27%
    Operating Margin13.79%
    Pretax Margin15.45%
    Net Margin11.58%
    EBITDA Margin15.66%
    EBIT Margin15.45%
    FCF Margin20.85%
    Gross Margin (5Y Average)65.91%
    Operating Margin (5Y Average)-82.13%
    Net Margin (5Y Average)-64.55%

    Growth

    Revenue grew 45.45% a year over 3 years, and EPS fell 34.14% a year.

    Revenue Growth (3Y CAGR)+45.45%
    EPS Growth (3Y CAGR)-34.14%
    FCF Growth (3Y CAGR)+188.15%
    Operating Income Growth (3Y CAGR)+99.18%
    Book Value Per Share Growth (2Y CAGR)+9.08%
    Tangible Book Per Share Growth (2Y CAGR)+9.79%

    Revenue and profit by year

    Dividends and Yields

    KNSA does not pay a dividend. Its free cash flow yield is 2.65%.

    Earnings Yield1.37%
    FCF Yield2.65%
    Buyback Yield-0.52%
    Shareholder Yield-0.52%

    Peer Position

    Against 10 similar companies, KNSA has the 2nd highest P/E.

    P/E Ratio73.2x vs 19.9x median
    P/S Ratio7.9x vs 3.0x median
    Revenue Growth (Trailing 4 Quarters, YoY)+58.19% vs +11.47% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 39.84% and EPS growth at 71.74% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+39.84%
    EPS Growth Forecast (2Y CAGR)+71.74%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About KNSA

    What is KNSA's market cap?

    Kiniksa Pharmaceuticals has a market cap of $7.40B. Its enterprise value, which adds debt and subtracts cash, is $7.32B.

    What is KNSA's P/E ratio?

    Kiniksa Pharmaceuticals has a trailing P/E ratio of 73.2x and a forward P/E of 72.5x.

    How many shares of KNSA are outstanding?

    Kiniksa Pharmaceuticals has 78.19M shares outstanding. The count is up 4.65% from a year earlier.

    Does KNSA pay a dividend?

    No. Kiniksa Pharmaceuticals does not pay a dividend.

    How much debt does KNSA have?

    Kiniksa Pharmaceuticals has $0 of total debt and $81.66M of cash and equivalents, a net cash position of $81.66M.